The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

If you are wondering whether Pfizer's current share price offers value for what you are getting, this article breaks down the numbers so you can assess that for yourself. Pfizer's share price last ...

Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer stock is a deep-value kind of blue chip with a yield of more than 7%. The dividend looks safe — for now. The real question is whether there’s enough growth and innovation in the pipeline as the ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with ...